MICROSCOPY AND CELL ANALYSIS SHARED RESOURCE PROJECT SUMMARY Decoding mechanisms in cancer biology requires a fundamental understanding of the relationship between structure and function. This is especially important for assessing tissue/tumor cell context, and at the macomolecular level, for organelle function and integrity, and chromosome structure and behavior. The Microscopy and Cell Analysis Shared Resource (MIC) provides exceptionally maintained high-end equipment for optical and electron microscopy, cytometry and cell sorting, and provides the technical expertise for their use to Mayo Clinic Cancer Center (MCCC) members conducting clinical or basic science cancer research. This shared resource is heavily used with 161 MCCC members using the facility in 2017, from each of the MCCC sites. The facility operates 10 hours/day on weekdays and 6 hours/day on weekends for assisted use, and for most areas 24/7 for unassisted use. The MIC provides access, training, and expertise for a wide array of state- of-the-art light and electron microscopy instrumentation, and for cell sorting and analysis. Our portfolio of instrumentation allows MCCC members to image single molecules, in live cells and tissues, or fixed specimens at optical or electron microscopic resolution, to analyze image data files by a wide variety of image analysis and 3D reconstruction packages, and to perform multi-color flow analysis and sorting of fixed or live cells. We support advanced optical imaging techniques such as FRET, TIRF, PALM, multi-photon, and 3D serial electron microscopy, as well as state-of-the-art flow cytometry and cell sorting instrumentation and analysis methods. The facility has aggressively pursued instrumentation funding which has allowed us to recently obtain a Zeiss Elyra super-resolution microscope, and this past year, a FEI Apreo Serial Block Face Electron Microscope. The MIC also provides cyberinfrastructure for data analysis, transfer, and storage of extremely large image data sets.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944

Showing the most recent 10 out of 1129 publications